Abstract
Anti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisiae fungemia with high anti-IL-23 autoantibodies, which was successfully treated using the novel application of daratumumab, resulting in significant clinical and laboratory improvements.